Tarsus Pharmaceuticals Stock Performance
| TARS Stock | USD 43.25 1.85 4.47% |
The entity has a beta of 0.55, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. At this point, Tarsus Pharmaceuticals has a negative expected return of -0.15%. Please make sure to validate Tarsus Pharmaceuticals' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to decide if Tarsus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Tarsus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 4.47 | Five Day Return 9.49 | Year To Date Return (21.58) | Ten Year Return 110.16 | All Time Return 110.16 |
1 | Tarsus Pharmaceuticals Inc Announces Upcoming Webcast for Q1 2025 Financial Results ... | 04/24/2025 |
2 | Tarsus Pharmaceuticals Loses -15.59 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner | 05/14/2025 |
3 | Disposition of 16975 shares by Azamian Bobak R. of Tarsus Pharmaceuticals subject to Rule 16b-3 | 05/16/2025 |
4 | OMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. | 05/20/2025 |
5 | TARS HC Wainwright Co. Initiates Buy Rating with 72 Target TARS Stock News | 05/27/2025 |
6 | Tarsus Pharmaceuticals Inc Announces Participation in Upcoming Investor Conferences ... | 05/29/2025 |
7 | Tarsus Pharmaceuticals Promising Outlook with Successful Xdemvy Launch and Strategic Growth Initiatives - TipRanks | 06/03/2025 |
8 | Disposition of 17500 shares by Mottiwala Aziz of Tarsus Pharmaceuticals at 43.76 subject to Rule 16b-3 | 06/09/2025 |
9 | Acquisition by Link William J Phd of 2954 shares of Tarsus Pharmaceuticals subject to Rule 16b-3 | 06/12/2025 |
10 | Disposition of 3350 shares by Link William J Phd of Tarsus Pharmaceuticals subject to Rule 16b-3 | 06/13/2025 |
11 | Disposition of 1006 shares by Lin Elizabeth Yeu of Tarsus Pharmaceuticals at 41.08 subject to Rule 16b-3 | 06/16/2025 |
12 | Disposition of 13608 shares by Jeffrey Farrow of Tarsus Pharmaceuticals at 40.42 subject to Rule 16b-3 | 06/17/2025 |
13 | Tarsus Pharmaceuticals, Inc. dropped from Russell Microcap Growth Index - MarketScreener | 06/30/2025 |
14 | William Blair Has Pessimistic Outlook of TARS Q2 Earnings | 07/16/2025 |
| Begin Period Cash Flow | 224.9 M | |
| Total Cashflows From Investing Activities | -199.2 M | |
| Free Cash Flow | -84.6 M |
Tarsus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 4,851 in Tarsus Pharmaceuticals on April 20, 2025 and sell it today you would lose (526.00) from holding Tarsus Pharmaceuticals or give up 10.84% of portfolio value over 90 days. Tarsus Pharmaceuticals is currently does not generate positive expected returns and assumes 2.6169% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Tarsus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tarsus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tarsus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tarsus Pharmaceuticals, and traders can use it to determine the average amount a Tarsus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0577
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TARS |
Estimated Market Risk
| 2.62 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tarsus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tarsus Pharmaceuticals by adding Tarsus Pharmaceuticals to a well-diversified portfolio.
Tarsus Pharmaceuticals Fundamentals Growth
Tarsus Stock prices reflect investors' perceptions of the future prospects and financial health of Tarsus Pharmaceuticals, and Tarsus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tarsus Stock performance.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 42.01 M | ||||
| Price To Book | 4.98 X | ||||
| Price To Sales | 7.78 X | ||||
| Revenue | 182.95 M | ||||
| Gross Profit | 161.56 M | ||||
| EBITDA | (106.48 M) | ||||
| Net Income | (115.55 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 72.45 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 8.15 X | ||||
| Cash Flow From Operations | (83.03 M) | ||||
| Earnings Per Share | (2.70) X | ||||
| Market Capitalization | 1.82 B | ||||
| Total Asset | 376.99 M | ||||
| Retained Earnings | (360.21 M) | ||||
| Working Capital | 276.09 M | ||||
About Tarsus Pharmaceuticals Performance
Assessing Tarsus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Tarsus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tarsus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 74.56 | 70.83 | |
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.51) | (0.49) |
Things to note about Tarsus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tarsus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tarsus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 161.56 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: William Blair Has Pessimistic Outlook of TARS Q2 Earnings |
- Analyzing Tarsus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tarsus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tarsus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tarsus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tarsus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tarsus Pharmaceuticals' stock. These opinions can provide insight into Tarsus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.